THE SEVENTH ESWI INFLUENZA CONFERENCE

#ESWI2020 VIRTUAL EDITION

6-9 DECEMBER 2020
The Organising Committee of the Seventh ESWI Influenza Conference was very excited to launch the Virtual edition of #ESWI2020.

We felt it is has never been more important to connect and come together with influenza, RSV disease, COVID-19 experts and policy makers. COVID-19 has clearly shown that a previously unknown pathogen may strike at any time, in any place and without any warning. There is a clear need for countries to have the capacity to maintain effective alert and response systems to detect and quickly react to outbreaks and to share information about such outbreaks rapidly and transparently.

ESWI has been putting influenza pandemic preparedness on the agenda of society for 3 decades now. Influenza and COVID-19 clearly have overlapping pandemic preparedness strategies. Policy makers and scientists responsible for managing this raging COVID-19 pandemic have turned to historical experience with influenza pandemics and for good reason. Intervention strategies perspectives need to be addressed urgently and the clinical perspectives and pathogenesis perspectives of influenza virus, RSV and SARS-CoV-2 need to be discussed between peers and stakeholders.

We had hoped to reschedule the Seventh ESWI Influenza Conference “live version” later at the beginning of December, but in September already it became clear that large gatherings would still be prohibited and existing travel bans would still be in place, and additionally we wanted to prioritize the health and safety of our faculty and attendees. We had therefore decided to go ‘virtual’, and to make the 7th ESWI Influenza Conference a virtual Conference.
This was our programme:
Monday 7 December

Morning welcome lecture: Antiviral and Immune Modifiers for Treatment of Influenza, RSV and COVID-19

Time: Monday 7 December, 08:00 – 08:30 CET

Track: Keynote lectures

Speaker: Michael Isra, Northwestern University

Webinar: Clinical manifestations of Influenza, RSV and COVID-19

Time: Monday 7 December, 08:00 – 10:00 CET

Chair: Al-Peterbus, Tilburg, Netherlands

1. Clinical signs and symptoms: overlap and differences
   - Barbara Roth, Vienna Vaccine Safety Initiative, DE
2. Risk groups: overlap and difference
   - Daniel Fokin, World Health Organization, CH
3. Clinical guidelines and symptomatic treatment
   - Peter Openshaw, Imperial College London, UK
4. Co-infections: Possible sequela's
   - Bruno Lima, Universidade de Lyon, FR

Good morning with Colin Russell

Time: Monday 7 December, 09:00 – 09:15 CET
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020

Monday 7 December, 12:00 - 13:00 CET
Special keynote lecture Janssen: Immunology underpinning vaccine strategy in COVID-19

TIME
Monday 7 December, 12:00 - 13:00 CET

TRACK
Keynote lectures

SPONSOR
Peter Openshaw, Imperial College London

Monday 7 December, 12:00 - 13:00 CET
Satellite symposium organised by the Influenza Diabetes Community, supported by Sanofi Pasteur: influenza in persons living with diabetes. Pathogenesis and prevention

TIME
Monday 7 December, 10:00 - 12:00 CET

TRACK
Satellite sessions

SPONSOR
Marta Guzmán-Jarreta, eminent MC

FORES: Xavier Cal, Primary Care Diabetes Europe/ Institute Catali di la salut

PROGRAM:
1. The impact of influenza on people with diabetes
   Marta Guzman-Jarreta, Eminent MC, The Netherlands

2. Influenza vaccination and people with diabetes: a must!
   Pratasha Baksh, cystic Fibrosis Trust, England, UK

3. Recent findings in glycanic variability and influenza severity
   Linda Shortt, University of Queensland, Australia

4. How to increase vaccination coverage in people with diabetes, the UK case
   Dave Crossman, Diabetes UK, United Kingdom

5. Diabetes during the COVID-19 pandemic
   Ab sterrenbos, TNO, Netherlands, Germany

Monday 7 December, 12:00 - 13:00 CET
Keynote lecture: SARS-CoV2: the hamster infection model, developing antiviral strategies and a unique single dose vaccine based on the yellow fever vaccine

TIME
Monday 7 December, 12:00 - 13:00 CET

TRACK
Keynote lectures

SPONSOR
Janet News, University of Leuven

Monday 7 December, 12:00 - 13:00 CET
Poster Session with Brooke Nichols

TIME
Monday 7 December, 12:00 - 13:00 CET

TRACK
Poster lectures

SPONSOR
Colin Russell discusses trending posters.
### Viral and host factors in the pathogenesis of influenza, RSV disease and COVID-19, including genomics and big data

**SCS**

**TIME:** Monday 7 December, 10:30 - 12:00 CET

**Track:** Scientific Programme

**CHAIR:** Barney Graham, Vaccine Research Center, NIAID, NIH

**SCIENTISTS:**

1. **Cytokine expression dynamics in the lung regulate antiviral response pathways against influenza A virus infection**
   - Sebastian Bach, Vital Dommisse, Ole Hetten, Peter Hofhuis. Ludwig Institute for Experimental Oncology, Heidelberg, Germany.

2. **Adaptation of an H5N1 H5N1 virus to the forest central nervous system?**
   - Junji Y. Shinya, Dept of Neuroscience, Delft MC, Rotterdam, the Netherlands.

3. **Comparative genomics and transcriptomics help unravel why Australian Black Swans are uniquely susceptible to highly pathogenic avian influenza (HPAI)**
   - Anjana Anand, School of Chemistry and Molecular Biosciences, University of Queensland, Australia. Australian Centre for Ecovirology, Australia.

4. **Reservoirs for future pandemics: threats from the animal world**
   - Abhishek Singh, Vaccine Research Center, NIAID, NIH.

**PROGRAMME:**

1. Cytokine expression dynamics in the lung regulate antiviral response pathways against influenza A virus infection
   - Sebastian Bach, Vital Dommisse, Ole Hetten, Peter Hofhuis. Ludwig Institute for Experimental Oncology, Heidelberg, Germany.

2. Adaptation of an H5N1 H5N1 virus to the forest central nervous system?
   - Junji Y. Shinya, Dept of Neuroscience, Delft MC, Rotterdam, the Netherlands.

3. Comparative genomics and transcriptomics help unravel why Australian Black Swans are uniquely susceptible to highly pathogenic avian influenza (HPAI)
   - Anjana Anand, School of Chemistry and Molecular Biosciences, University of Queensland, Australia. Australian Centre for Ecovirology, Australia.

4. Reservoirs for future pandemics: threats from the animal world
   - Abhishek Singh, Vaccine Research Center, NIAID, NIH.

**Reservoirs for future pandemics: threats from the animal world**

**SCS**

**TIME:** Monday 7 December, 10:30 - 12:00 CET

**Track:** Scientific Programme

**CHAIR:** Abhishek Singh, Vaccine Research Center, NIAID, NIH

**SCIENTISTS:**

1. **Co-infections with low and high pathogenic avian influenza H5N1 and H7N9 viruses demonstrate that H7N9 are more likely to emerge in chickens than in ducks**
   - Pierre Brixiova, Université de Neuchâtel, NEZM H5N1 France.

2. **Antigenic characterisation of novel H1 and H5 influenza A viruses in swine**
   - Rodrigo Tojo, Departamento de Medicina Preventiva Animal, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago, Chile.

3. **Characterizing the functional diversity of the Wolbachia SpA Imply in Influenza Virus Surface Glycoprotein**
   - Uladzimir Andreichuk, Dept of Microbiology, School of Medicine at Mount Sinai, New York, NY, USA.

4. **Influenza A virus: a potential threat for humans?**
   - Claudia Tiernek, University of Siena, Italy.

### Influenza, RSV disease and COVID-19 intervention strategies: current practice and future strategies

**SCS**

**TIME:** Monday 7 December, 16:00 - 18:00 CET

**Track:** Science Policy Interface

**CHAIR:** Manon de Jong, University of Amsterdam

**PROGRAMME:**

1. **Suppressing COVID-19 transmission in three epidemic waves in Hong Kong**
   - Peng-Sheng, W.H. Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

2. **Pre-pandemic and pandemic vaccines**
   - Peter Murrell, Dept of Microbiology at Mount Sinai, United States.

3. **Antivirals resistance, RSV, COVID-19: key recent developments**
   - Prokopios Pavlakis, Professor Emofcell Medicine, United States of America.

4. **Non-medicinal interventions**
   - Agnieszka Rollins, European Centre for Disease Prevention and Control, Sweden.

5. **Regulatory requirements of vaccine development**

**Reservoirs for future pandemics: threats from the animal world**

**KEY**

**TIME:** Monday 7 December, 16:00 - 18:00 CET

**Track:** Keynotes lectures

**PROGRAMME:**

1. **Opening remarks**
   - Michael S. Levine, Northwestern University, United States of America.

2. **Beyond Vaccines and medications: Progress Towards Universal Influenza Protection with CloudBreak X Conjugates (UXC)**
   - Leslie Tan, CloudBreak Therapeutics, United States of America.

### Meet Cam Russell and Harro Goejnen in the lounge

**TIME:** Monday 7 December, 16:00 - 18:00 CET
Tuesday 8 December

Tuesday 6 December, 08:00 - 10:00 CET
Morning welcome lecture: Host cell factors that impact the emergence of pandemic respiratory viruses

Tuesday 6 December, 06:00 - 08:10 CET
Keynote lectures

Speaker: Wendy Barlow, Imperial College London

Tuesday 8 December, 06:00 - 11:00 CET
Webinar: Intervention strategies for COVID-19, influenza and RSV

Speaker: Ab Osterhaus, TUM, Hannover
   1. Current strategies
   2. Testing and testing consequences
   3. Influenza vaccination during COVID-19
   4. Antivirals & Biological Response Modifiers

Speaker: Mike Bowie, Northwestern University, USA

Tuesday 6 December, 09:00 - 09:15 CET
Good morning with Brooke Nichols
Tuesday 6 December, 09:00 - 09:30 CET
Meet the expert (sponsored by Roche): Strategies to Reduce Influenza Transmission - limited availability, registration required

Speaker:
- Andreas Werner, University of Basel
- Lee Yiu Yung Lee, Peter Doherty Institute for infection and immunity

Tuesday 6 December, 10:00 - 10:30 CET
Keynote lectures: COVID-19 vaccine development: where are we?

Speaker:
- Mollie Lua, CEPPI

Tuesday 6 December, 10:30 - 11:00 CET
Influenza, RSV disease and COVID-19: clinical impact and diagnostic approaches (including disease management in primary healthcare and hospital settings)

Speaker:
- Hans Geijtenbeek, Erasmus MC
- Trissoon Clark, University of Southampton

Program:
1. Clinical impact of Molecular Point-of-Care Testing for COVID-19 in Adults Presenting to Hospital: A Prospective, Interventional, Non-Randomised, Controlled Study [COVID19]PC
   - Hans Geijtenbeek, Erasmus MC
   - Trissoon Clark, University of Southampton

Tuesday 6 December, 10:45 - 11:45 CET
Satellite symposium organised by BioNTech: The Road to COVID-19 Vaccine Development

Speaker:
- Satellite sessions

Program:
1. Welcome Address
   - David Hopkins, LUPH, United Kingdom

2. Accelerated Development: How COVID-19 Vaccines are Being Developed Safely in Record Time
   - Peter Openshaw, Oxford Vaccine Group, United Kingdom

3. Platforms to Launch: The Cutting-Edge Technologies Underpinning COVID-19 Vaccines in Development
   - Dr. Richard Member, University of Pennsylvania, United States of America

4. Latest Data and Insights: COVID-19 Vaccine Candidates
   - Robert Freimuth, Cincinnati Children’s Hospital, United States of America

5. Panel Q&A
   - David Hopkins, LUPH, United Kingdom

   - David Hopkins, LUPH, United Kingdom

7. Final Summary & Close
   - David Hopkins, LUPH, United Kingdom

Tuesday 6 December, 14:00 - 14:30 CET
Keynote lecture: Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards

Speaker:
- Jarle Krarud, Ullebø University

Program:
1. Lethal and near-lethal mutagenesis: Changes in fitness and mutation rate during the treatment of respiratory syncytial virus with ribavirin and foscarnet
   - Chris Ellingsworth, University of Cambridge, United Kingdom

2. Poised nasal and throat swabs, nasal swabs and saliva as alternative clinical specimens for the diagnosis of COVID-19: a systematic review and meta-analysis
   - Ngap Yeh Tong, National Institute of Medical Research, Singapore

3. Clinical studies on the role of SARS-CoV-2 in HIV-1-infected individuals
   - Andrew Sebire, University of Cambridge, United Kingdom

4. The impact of respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) on the respiratory tract of children with cystic fibrosis
   - Edith Ellingsworth, University of Cambridge, United Kingdom
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020

Tuesday 8 December, 14:00 - 16:00 CET
Antiviral and immune therapy for influenza, RSV disease and COVID-19

Chair:
Frederick Haydon, Professor Emeritus of Medicine
Joanne Brindle, University of Sheffield

Program:
1. Combining baloxavir with standard-of-care (SoC) neuraminidase inhibitor (NAI) in patients hospitalised with severe influenza: results from the global randomised phase 3 FLAVSTONE study
Deepali Kumar, University Health Network, Toronto, Ontario, Canada

2. Structural and functional characterization of a SARS-CoV-1 and -2 cross-neutralizing single domain antibody and their clinical potential
Xavier Serrano, Ghent University and VIB, Belgium

3. Treatment Emergent Resistance to the Influenza Antiviral Baloxavir: Pooled Analysis of Baloxavir Clinical Trials
Jharna K.i., Genentech, Inc., South San Francisco, CA, United States of America

Jeffrey Lopaka, Usha Therapeutics, United States of America

Tuesday 8 December, 16:00 - 18:00 CET
Satellite symposium organised by Roche: Can we stop flu going viral?

Chair:
Frederick Haydon, Professor Emeritus of Medicine

Program:
1. Welcome and introduction
Frederick Haydon, Professor Emeritus of Medicine, United States of America

2. Antiviral treatment in hospitalised patients: Setting the scene
Frederick Haydon, Professor Emeritus of Medicine, United States of America

3. Antiviral treatment in hospitalised patients
Jean-Paul Mira, Centre Hospitalier Paris-Centre, France

4. Role of antiviral treatment in reducing the spread of influenza: Setting the scene
Frederick Haydon, Professor Emeritus of Medicine, United States of America

5. Role of antiviral treatment in reducing the spread of influenza
Laurie Mocro, The University of Texas at Austin, United States of America

6. Panel discussion with Jean-Paul Mira, Lauren Meyers, Henee de Jong, Deepali Kumar, Benjamin Coupling, Toruh Herikom
Frederick Haydon, Professor Emeritus of Medicine, United States of America

7. Summary and closing remarks
Frederick Haydon, Professor Emeritus of Medicine, United States of America
### Wednesday 9 December

#### Morning welcome lecture: Risk factors for severe outcomes following COVID-19 infection - results of a systematic literature review

**TIME:** Wednesday 9 December, 08:00 - 08:15 CET  
**TRACK:** Keynote lectures  
**SPONSOR:** Post Pandemics, European Centre for Disease Prevention and Control (ECDC)

#### Webinar: Cornerstones of pandemic preparedness and urgent actions

**TIME:** Wednesday 9 December, 08:00 - 10:00 CET  
**TRACK:**  
**CHAIR:** Ana Olavarria, Tübingen, Hannover  
1. Vaccines  
   - Ana Olavarria, Tübingen, Hannover, Germany  
   - Jonathan Andrews, Sydney, Australia  
2. Antivirals  
   - Frederick Hayden, University of Virginia, USA  
3. Non-medical interventions  
   - Angélique Hebbelinck, ECDC, Sweden  
4. Cross-sector collaboration and communication  
   - Sylvie Brand, World Health Organisation, Switzerland

#### Recap of the day: Highlights with Colin Russell and Marco Geeljenber

**TIME:** Tuesday 8 December, 20:00 - 20:30 CET  
**TRACK:**  
**CHAIR:** Colin Russell, Marco Geeljenber

#### Satellite symposium organised by Sanofi Pasteur: 10 years of evidence using high dose influenza vaccine in people age 65 and older

**TIME:** Tuesday 8 December, 18:00 - 20:00 CET  
**TRACK:** Satellite sessions  
**CHAIR:** Ruediger Holmgren, Sanofi Pasteur

1. Opening remarks  
Ruediger Holmgren, Sanofi Pasteur, United States of America
2. The burden of influenza disease in people 65 years old and over  
Thomas Winkel, Aachen Technical University, Germany
3. High dose influenza vaccine: benefits for older adults  
Marc Van Ranst, University of Leuven, Belgium
4. North America experience: high dose vaccine focus on long term care  
Jonathan Andrews, Sydney, Australia
5. Q&A and Closing Remarks with Thomas Winkel, Marc Van Ranst, and Stefan Groensteijn  
Ruediger Holmgren, Sanofi Pasteur, United States of America
THE SEVENTH ESWI INFLUENZA CONFERENCE #ESWI2020

Wednesday 9 December, 08.00 - 08.30 CET
Meet the expert (sponsored by Roche): Management of Hospitalised Patients with Severe Influenza - limited availability, registration required

SPEAKER:
Tristan Clark, University of Southampton
Jean-Paul Avis, Centre Hospitalier Paris Centre

Wednesday 9 December, 08.00 - 09.30 CET
TALKS
Keynote lectures

SPEAKERS:
Tristan Clark, University of Southampton
Jean-Paul Avis, Centre Hospitalier Paris Centre

Supported by Roche

Wednesday 9 December, 10.00 - 12.00 CET
Satellite symposium organised by ESPID and ESWI. Should we introduce national live vaccination programmes for children?

TALKS:
Satellite sessions

SPEAKERS:
Tarke Helmersen, University of Turku

AstraZeneca has provided a sponsorship grant towards this independent Programme

PROGRAMME:
   Tarke Helmersen, University of Turku, Finland

2. Efficacy and safety of seasonal influenza vaccination in children
   Alex Dietze, City, Vancouver, Canada

3. The burden of paediatric influenza in the US: mortality, hospitalisations, outpatient visits and other outcomes
   Palmyra Kent, Children's National Hospital and Clinics of Minnesota, United States of America

4. How to increase vaccine confidence and counter parental doubts on the safety and effectiveness of influenza vaccines?
   Hanna Lyytikäinen, Helsinki Institute for Health and Social Affairs, Finland

5. Debate: should we introduce live vaccination programmes for children?
   Tarke Helmersen, University of Turku, Finland

Wednesday 9 December, 12.00 - 15.00 CET
Influenza, RSV disease and COVID-19 vaccination: current and future approaches

TALKS:
Scientific Programme

SPEAKERS:
Peter Opalakou, Imperial College London
Dennis Lemen, University Hospital Eindhoven

PROGRAMME:
1. Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model
   Melanie H. Reus, Department of Virology, Ludwig-Maximilians-Universität, Munich, Germany

2. Antigen-modifications improve mRNA-based influenza virus vaccine efficacy in mice
   Allan W. Pross, Department of Microbiology, Johns Hopkins School of Medicine, Baltimore, MD, USA

3. A 10-mer mucosal vaccine adjuvant: Specific induction of tissue-resident memory T cells and enhanced protection against heterogeneous SW
   Ernesta Lavrazins, Institute of Clinical and Molecular Virology, University Hospital Eindhoven, Netherlands

4. A comprehensive influenza reporter virus panel for deconvoluting polyvalent sera using neutralization maps
   Adrian C Horsa, National Institute of Allergy and Infectious Diseases, United States of America

5. CELL RESPONSE 2: Relative vaccine effectiveness against influenza-related hospitalizations and serious respiratory events during the 2018/19 influenza season in children and adults. Comparison between quadrivalent cell-based and egg-based influenza vaccines
   Giuseppe Federico, World Health Organization, Severe Acute Events Unit, Boston, MA, USA
Wednesday 9 December, 14:00 - 16:00 CET
Keynote lectures: Vaccine confidence in a time of covid

**TIME:**
Wednesday 9 December, 14:00 - 14:15 CET

**TRACK:**
Keynote lectures

**SPONSOR:**
Health Lottery, London School of Hygiene & Tropical Medicine

---

Wednesday 9 December, 14:00 - 16:05 CET
Co-infections in influenza, RSV disease and COVID-19

**TIME:**
Wednesday 9 December, 14:00 - 16:05 CET

**TRACK:**
Scientific Programme

**CHAIR:**
Ed Mitchell, University of Glasgow

**PROGRAMME:**
1. The burden and clinical characteristics of viral respiratory disease before and during the SARS-CoV-2 pandemic
   - Stephanie Finley, SMH Stratified Causal Research Centre, Southampton, United Kingdom
   - University Hospitals Southampton NHS Trust

2. Evaluation and selection of influenza a virus defective interfering particles in a semi continuous production system for the use as antiviral
   - Loris Filleti, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

3. Superinfection exclusion limits genome interactions during localized spread of influenza A viruses.
   - Anna Sere, MRC University of Glasgow Centre for Virus Research, United Kingdom

4. Aspergillosis Complicating Severe Influenza and Respiratory Syncytial Virus (RSV) in ICU Patients
   - Ksenia M. Pyshmyan, Kharkiv National University of Medicine, Kharkiv, Ukraine
   - University of California, Irvine, United States of America

---

Wednesday 9 December, 14:00 - 16:05 CET
Risk evaluation and communication strategies in influenza and COVID-19: lessons learned

**TIME:**
Wednesday 9 December, 14:00 - 15:30 CET

**TRACK:**
Science Policy Interface

**CHAIR:**
Paul Sucheston, European Centre for Disease Prevention and Control (ECDC)

**PROGRAMME:**
1. Cross-sectoral collaboration and communication
   - Tim Nijmeijer, World Health Organization, Switzerland

2. The role of experts in guiding policy
   - Peter Openshaw, Imperial College London, United Kingdom

3. Reaching out to people at risk: focus on the elderly: why and how
   - Janet Milliken, Health Sciences North Research Institute, Canada

4. Talking vaccines in risky business: challenges in the post-trust environment
   - Fredric Bredesen, University of Oregon, Oregon

---

Wednesday 9 December, 14:00 - 16:06 CET
Late Breakers: novel and outstanding scientific discoveries

**TIME:**
Wednesday 9 December, 14:00 - 16:06 CET

**TRACK:**
Science Policy Interface

**CHAIR:**
Marieke Duveends, PANVAC

**PROGRAMME:**
1. The SARS-CoV-2 and other human coronaviruses spike proteins are fine-tuned towards temperature and proteases of the human airways
   - Manuela Loppnau, AVL Innsbruck, Austria
   - Institute for Medical Research, Belgium

2. The avian-to-human adaptation of the 1968 A/H3N2 pandemic influenza virus
   - Dorothy Meanwell, Department of Virology, Academic Medical Center, Amsterdam, Amsterdam, The Netherlands

3. Phase 1 trial results of a Candidate Reemergent Virus-Like Particulate Vaccine for Covid-19 Disease Produced in Plants and Adjuvanted with GST's Panvaccin Faden
   - Bruce J. Word, NRG, USA
   - Canada Research Institute of the McGill University, Canada

4. The contracting within-host evolutionary dynamics between seasonal and pandemic human influenza A viruses
   - Alison F. Grant, Laboratory of Applied Virology, Netherlands
   - Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

5. Acute, Suprapharmacologic Desmopressin Nebulized Natural Killer T and Cytotoxic T cells for Influenza A/B-induced or COVID-19-induced ARDS
   - Thomas Delia, AstraZeneca, United States of America

---

Wednesday 9 December, 14:00 - 16:08 CET
Burdens of Influenza, RSV disease and COVID-19 and its impact on society

**TIME:**
Wednesday 9 December, 14:00 - 16:08 CET

**TRACK:**
Science Policy Interface

**CHAIR:**
Rebecca Cox, University of Hong Kong
- Kathy Tung, University of Hong Kong

**PROGRAMME:**
1. Mortality Associated with Seasonal Influenza Epidemics in the European Union: Overall Estimates Based on Respiratory Mortality from 2002-2013
   - John Pogreb, ISV, Grenoble, France

2. Excess Mortality and Healthcare Resource Use Attributed to Influenza in People at High Risk for Developing Complications: Real World Evidence from a US Managed Care Population
   - Susan C. Bridges, Lerner Global Services, LLC, Partner, USA

3. A Systematic Literature Review and a Meta-analysis of the Respiratory Syncytial Virus (RSV) Burden of Disease in Adults Over 50 Years of Age
   - Willy Torn, CDA, Ghent, Belgium

4. The disease burden of respiratory syncytial virus infection in young children in primary care: results from the RSV Comet pilot in Italy and the Netherlands
   - Joaquim L. Pinto, San Servanimento, Italy
   - Netherlands Institute for Health Services Research, Utrecht, Netherlands, The
Proceedings of the conference will be Special Issue of Vaccine, Elsevier.

Separate report of the Science Policy Interface track is disseminated end of December 2020 and downloadable on the influenzaconference.org site.